The overall survival benefit of pembrolizumab monotherapy was demonstrated in untreated stage IV NSCLC patients compared to chemotherapy in patients with tumors expressing a PD-L1 tumor proportion score (TPS) ≥ 50%, TPS ≥ 20%, and TPS ≥ 1% in randomized phase III clinical trials [10,11,12]. Here, CD274 is linked to non-small cell lung carcinoma.